EVEREST MED.LTD DL-0001 Market Cap ($1.13 Billion)
Market Cap & Net Worth: EVEREST MED.LTD DL-0001 (6HN)
EVEREST MED.LTD DL-0001 market cap. EVEREST MED.LTD DL-0001 (F:6HN) has a market capitalization of $1.13 Billion (€967.10 Million) as of November 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #8082 globally and #1095 in its home market, demonstrating a -20.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EVEREST MED.LTD DL-0001's stock price €2.74 by its total outstanding shares 352955022 (352.96 Million). Also see EVEREST MED.LTD DL-0001 cash conversion from operations for how efficiently the company converts equity into cash flow.
EVEREST MED.LTD DL-0001 Market Cap History (2020–2026)
EVEREST MED.LTD DL-0001 market cap history from 2020 to 2026. Data shows change from $2.83 Billion to $1.13 Billion (-16.61% CAGR). Check EVEREST MED.LTD DL-0001 share price for real-time trading data and today's change.
EVEREST MED.LTD DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EVEREST MED.LTD DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore EVEREST MED.LTD DL-0001 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.98x
EVEREST MED.LTD DL-0001's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.48 Billion | $54.00K | -$1.01 Billion | 27356.60x | N/A |
| 2022 | $821.98 Million | $12.79 Million | -$247.28 Million | 64.26x | N/A |
| 2023 | $949.08 Million | $125.93 Million | -$844.46 Million | 7.54x | N/A |
| 2024 | $2.33 Billion | $706.68 Million | -$1.04 Billion | 3.30x | N/A |
| 2025 | $1.67 Billion | $1.71 Billion | -$297.77 Million | 0.98x | N/A |
Competitor Companies of 6HN by Market Capitalization
Companies near EVEREST MED.LTD DL-0001 in the global market cap rankings as of November 5, 2026. Also see EVEREST MED.LTD DL-0001 total assets for a full breakdown of the balance sheet.
Key companies related to EVEREST MED.LTD DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of EVEREST MED.LTD DL-0001 (2020–2026)
Market capitalization of EVEREST MED.LTD DL-0001 from 2020 to today. Between 2020 and today, EVEREST MED.LTD DL-0001's market cap moved from $2.83 Billion to $ 1.13 Billion, with a yearly change of -16.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.13 Billion | -32.18% |
| 2025 | €1.67 Billion | -28.50% |
| 2024 | €2.33 Billion | +145.65% |
| 2023 | €949.08 Million | +15.46% |
| 2022 | €821.98 Million | -44.36% |
| 2021 | €1.48 Billion | -47.74% |
| 2020 | €2.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of EVEREST MED.LTD DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more